Posts
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
- Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
- Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
- Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
- Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
arcticnovartis
- Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented
- Phase II data evaluating safety and efficacy results of remibrutinib for treatment of peanut allergy to be featured in an oral session
